LSTA

3 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)

LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company") today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026. Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board has determined that Mr. Farrow is independent under Nasdaq listing rules. "Jeff has helped take multiple companies from the clinic to approval and commercial launch, and he has led several of them through su

LIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company, today announced that the United States Patent and Trademark Office ("USPTO") has granted a new Method of Use patent for certepetide [U.S. Patent No. 12,751,991] for the treatment of pancreatic cancer and other solid tumors, expiring May 2041. The newly issued patent, titled "Methods for Treating Pancreatic Cancer and Other Solid Tumors," expands Lisata’s intellectual property protection for certepetide. The patent covers administering the Company’s proprietary cyclic peptide in combination with at least one anti-cancer agent

PRE 14A - LISATA THERAPEUTICS, INC. (0000320017) (Filer)

Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care By directly blocking growth hormone signaling at the receptor level, MAR002 has the potential to deliver meaningful biochemical control for a broad population of acromegaly patients SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, LLC ("Marea"), a subsidiary of Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), a clinical-stage biotechnology company

D - LISATA THERAPEUTICS, INC. (0000320017) (Filer)

3 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

3 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

SOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. ("Marea"), a subsidiary of Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that data from the Phase 2b TYDAL study of MAR001, a potential first-in-class monoclonal antibody targeting angiopoietin-like protein 4 (ANGPTL4), will be presented in a late-breaking science session at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9, 2026, in Chicago, Illinois. Pres

8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)

Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002 for the treatment of acromegaly which is advancing to a Phase 2 study Concurrent financing of $225 million from leading life sciences investors and other institutional investors projected to fund operations into 2028 LIBERTY CORNER, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), a clinical-stage pharmaceutical company, today announced that it has acquired Marea Therapeutics, Inc. ("Marea"), a

10-Q - LISATA THERAPEUTICS, INC. (0000320017) (Filer)

Lisata has filed suit against Kuva Labs Inc. and its subsidiary seeking, among other things, damages for the benefit of its stockholders Lisata’s Board of Directors and management continues to evaluate strategic alternatives to enhance stockholder value In order to reduce operating expenses and preserve cash to pursue strategic alternatives, Lisata has implemented a reduction in force of approximately 72% of its full-time employees LIBERTY CORNER, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today p

8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)

8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)

SC 14D9/A - LISATA THERAPEUTICS, INC. (0000320017) (Subject)

8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)

SC 14D9/A - LISATA THERAPEUTICS, INC. (0000320017) (Subject)

SC 14D9/A - LISATA THERAPEUTICS, INC. (0000320017) (Subject)

SC 14D9/A - LISATA THERAPEUTICS, INC. (0000320017) (Subject)

SC 14D9 - LISATA THERAPEUTICS, INC. (0000320017) (Subject)

Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to achievement of specified milestones The transaction valued Lisata at a significant premium to the historical market price of Lisata common stock prior to the announcement of the proposed transaction and provides potential additional upside if the specified milestones are achieved Lisata Board of Directors unanimously recommends stockholders to tender their shares The transaction is expected to close in the third quarter of 2026, subject to

SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)

8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)